Authors: Abou-Arab O, Huette P, Debouvries F, Dupont H, Jounieaux V
PMID: 33183348 PMCID: PMC7661015 DOI: 10.1186/s13054-020-03371-x
Abstract
The role of inhaled nitric oxide (iNO) in the management of severe hypoxia due to coronavirus disease 2019 (Covid-19) is a subject of debate. Despite the lack of clinical data, the surviving sepsis campaign recommended the use of iNO as a rescue therapy in such patients with persistent hypoxemia and, at the same time, reminded that this treatment must be tapered off in the absence of rapid improvement [1].
The aim of the present study is to record the effect of iNO administration in COVID-19 patients with severe pneumonia.
We conducted a single-center prospective study at Amiens Hospital University (France), (ancillary study of a prospective COVID-19 critically patient database registered on ClinicalTrials.gov: NCT04354558 and declared to the CNIL number: PI2020_843_0026).
Keywords: nitric oxide, COVID-19
